DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study
Brief description of study
The purpose of this study is to collect blood samples to determine if a blood-based test can be used to identify lung cancers that may or may not also be seen on images of lungs. Additionally, the study aims to see if a blood-based test can identify other types of cancers and health conditions.
Approximately 2500 patients in the United States will participate in this study. This will include approximately 1600 patients with cancer (600 with lung cancer and 1000 with another type of cancer) and approximately 900 patients without cancer.
Detailed description of study
The overall goal is to develop a cfDNA fragmentation-based algorithm with clinical performance metrics optimized to improve adherence to lung cancer screening guidelines while improving the benefits to harms ratio of serial LDCT surveillance. The specific objective is to train and test a novel classifier using a multi-site, observational study design. This is a prospectively enrolling observational case-control study. Peripheral blood will be collected from individuals enrolled in the cohort.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: Between 50 Years - 99 Years
-
Gender: All
Age >= 50 and Smoking history which meets the U.S. Preventive Services Task Force (USPSTF) criteria of being high risk for developing lung cancer.
Updated on
09 Mar 2024.
Study ID: 849987
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
